Tokyo, Japan

Mariko Yamabe

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Glaxosmithkline LLC. Active years: 2010.



Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mariko Yamabe: Innovator in Pharmaceutical Chemistry

Introduction

Mariko Yamabe is a distinguished inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for medical applications. Her work exemplifies the intersection of science and technology in addressing health challenges.

Latest Patents

Mariko Yamabe holds a patent for her invention titled "2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors." This patent encompasses 2-pyrimidinyl pyrazolopyridine compounds, compositions containing these compounds, as well as processes for their preparation and use as pharmaceutical agents. This invention represents a promising advancement in targeted therapies.

Career Highlights

Mariko is currently employed at GlaxoSmithKline LLC, where she continues to push the boundaries of pharmaceutical research. Her dedication to innovation has led to the development of new therapeutic agents that have the potential to improve patient outcomes.

Collaborations

Throughout her career, Mariko has collaborated with notable colleagues, including Alex Gregory Waterson and David Edward Uehling. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Mariko Yamabe's contributions to pharmaceutical chemistry and her innovative spirit make her a key figure in the field. Her work not only advances scientific knowledge but also holds the potential to impact healthcare positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…